Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
SAGA Metals Reports Assays from R-0058 to R-0060 with Intercepts Including 43.86% Fe2O3, 6.10% TiO2, 0.317% V2O5 from 2026 Drilling at Radar Critical Minerals Project in Labrador and Adds to Its Advisory Board
